Equilis StrepE


live vaccine against Streptococcus equi

This medicine is authorised for use in the European Union.


Equilis StrepE is a veterinary vaccine used to protect horses against the respiratory disease caused by the bacteria Streptococcus equi. The highly contagious and common disease caused by this bacterium is commonly called ‘strangles’. In strangles, the lymph nodes in the head can become large enough to block the airway, causing the horse to have difficulty breathing. This is a highly contagious disease and a common bacterial infection in horses. Equilis StrepE reduces the clinical signs of disease and the occurrence of lymph node abscesses (collections of pus).

Equilis StrepE contains the active substance live deletion mutant Streptococcus equi strain TW928.

This EPAR was last updated on 15/02/2021

Authorisation details

Product details
Equilis StrepE
Agency product number
Active substance
live deletion-mutant Streptococcus equi strain TW928
International non-proprietary name (INN) or common name
live vaccine against Streptococcus equi
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervet International BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

10/04/2014 Equilis StrepE - EMEA/V/C/000078 - II/0012/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for equidae

Therapeutic indication

For immunisation of horses against Streptococcus equi to reduce clinical signs and occurrence of lymph-node abscesses.

Onset of immunity: The onset of immunity is established as two weeks after basic vaccination.

Duration of immunity: The duration of immunity is up to three months.

The vaccine is intended for use in horses for which a risk of Streptococcus equi infection has been clearly identified, due to contact with horses from areas where this pathogen is known to be present, e.g. stables with horses that travel to shows or competitions in such areas, or stables that obtain or have livery horses from such areas.

Assessment history

How useful was this page?

Add your rating